Discounted Cash Flow (DCF) Analysis Levered

Pharmasimple SA (ALPHS.PA)

0.0002 €

+0.00 (+100.00%)
All numbers are in Millions, Currency in USD
Stock DCF: 87,374,001.72 | 0.0002 | undervalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 19.1717.1328.6546.4764.8890.57126.45176.53246.44
Revenue (%)
Operating Cash Flow -2.90-2.59-4.33-7.02-9.81-13.69-19.11-26.68-37.25
Operating Cash Flow (%)
Capital Expenditure ---------
Capital Expenditure (%)
Free Cash Flow --2.59-4.33-7.02-9.81-13.69-19.11-26.68-37.25

Weighted Average Cost Of Capital

Share price $ 0.0,002
Beta 1.573
Diluted Shares Outstanding 0
Cost of Debt
Tax Rate 0.93
After-tax Cost of Debt 1.31%
Risk-Free Rate
Market Risk Premium
Cost of Equity 11.126
Total Debt 7.89
Total Equity 0
Total Capital 7.89
Debt Weighting 100.00
Equity Weighting 0.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 19.1717.1328.6546.4764.8890.57126.45176.53246.44
Operating Cash Flow -2.90-2.59-4.33-7.02-9.81-13.69-19.11-26.68-37.25
Capital Expenditure ---------
Free Cash Flow --2.59-4.33-7.02-9.81-13.69-19.11-26.68-37.25
WACC
PV LFCF -9.81-13.51-18.62-25.66-35.36
SUM PV LFCF -101.62

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 1.31
Free cash flow (t + 1) -37.99
Terminal Value 5,505.91
Present Value of Terminal Value 5,159.02

Intrinsic Value

Enterprise Value 5,057.40
Net Debt 7.89
Equity Value 5,049.51
Shares Outstanding 0
Equity Value Per Share 87,374,001.72